hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06321276, orgStudyIdInfo id: AEU-FTR-ID-01, briefTitle: Investigation of the Efficiency of Radial Extracorporeal Shock Wave Therapy at Different Pulses in Carpal Tunnel Syndrome, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2024-04-15, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Ahi Evran University Education and Research Hospital, class: OTHER, descriptionModule briefSummary: Different parameters have been used in studies investigating the efficacy of extracorporeal shock wave therapy in the treatment of carpal tunnel syndrome. Although extracorporeal shock wave therapy has been shown to have a positive effect on carpal tunnel syndrome, there is no consensus on which pulse rate is more effective. Therefore, in this study, the efficacy of extracorporeal shock wave therapy applied at different pulse rates in the treatment of carpal tunnel syndrome will be examined., conditionsModule conditions: Carpal Tunnel Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: three groups with a conventional therapy control group, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Patient, whoMasked: INVESTIGATOR, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: extracorporeal shockwave therapy, outcomesModule primaryOutcomes measure: Visual analogue scale (VAS), primaryOutcomes measure: Boston Carpal Tunnel Syndrome Questionnaire, secondaryOutcomes measure: Hand grip strength measurement, secondaryOutcomes measure: Electromyoneurography (EMNG), secondaryOutcomes measure: Ultrasonography, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kirsehir Ahi Evran University, status: RECRUITING, city: Kırşehir, zip: 40100, country: Turkey, contacts name: ibrahim Doğru, MD, role: CONTACT, phone: 5353127880, phoneExt: +90, email: www.skillcraft@hotmail.com, contacts name: ismail ceylan, PhD, role: CONTACT, phone: 5364634679, phoneExt: +90, email: fztceylan@gmail.com, geoPoint lat: 39.14583, lon: 34.16389, hasResults: False
protocolSection identificationModule nctId: NCT06321263, orgStudyIdInfo id: 798307, briefTitle: Comparison of the Effects of Peripheral Muscle Training and Inspiratory Muscle Training in Geriatric Individuals, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2024-09-27, completionDateStruct date: 2025-03-21, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Biruni University, class: OTHER, descriptionModule briefSummary: In geriatric individuals, there is a decrease in muscle strength, muscle mass and physical performance with ageing. These physiological changes occurring in geriatric individuals make maintaining the physical activity necessary for a healthy life difficult. Weakness of respiratory muscles in geriatric individuals can increase the prevalence of diseases and disability. It has been shown in the literature that peripheral muscle training and inspiratory muscle training increase exercise capacity similarly. The effectiveness of moderate-intensity peripheral muscle training and inspiratory muscle training in sarcopenic geriatric individuals was compared and found to have similar effects on muscle strength.Our study aims to compare the effects of inspiratory and peripheral muscle training in addition to aerobic exercise on muscle strength, physical performance, respiratory muscle strength, functional capacity, sarcopenia, and quality of life., conditionsModule conditions: Muscle Strength, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Peripheral Muscle Training and step aerobics training, interventions name: Inspiratory Muscle Training and step aerobics training, outcomesModule primaryOutcomes measure: The sociodemographic data form, primaryOutcomes measure: Hand grip strength, primaryOutcomes measure: Maximal inspiratory and expiratory pressures (MIP, MEP), primaryOutcomes measure: 6-Minute Walk Test (6MWT), primaryOutcomes measure: The Short Physical Performance Battery (SPPB), primaryOutcomes measure: Assessment of seniors᾽ quality of life: WHOQOL-OLD questionnaire, secondaryOutcomes measure: SARC-F questionnaire, otherOutcomes measure: Canadian Occupational Performance Measure, eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 80 Years, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06321250, orgStudyIdInfo id: JY-JM3948-101, briefTitle: A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-28, primaryCompletionDateStruct date: 2026-05-31, completionDateStruct date: 2027-04-30, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Jemincare, class: INDUSTRY, collaborators name: Zhejiang Hangyu Pharmaceutical Co., Ltd, descriptionModule briefSummary: This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma., conditionsModule conditions: Renal Cell Carcinoma Metastatic, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: JMKX003948, outcomesModule primaryOutcomes measure: Dose Escalation: Number of participants with dose limiting toxicities (DLTs), primaryOutcomes measure: Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), primaryOutcomes measure: Dose Expansion: Objective Response Rate (ORR), secondaryOutcomes measure: maximum plasma concentration (Cmax), secondaryOutcomes measure: maximum plasma concentration (Tmax), secondaryOutcomes measure: Duration of Response (DoR), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06321224, orgStudyIdInfo id: 2024/03/08, briefTitle: Effects of Breathing Exercises on Women With Primary Dysmenorhea, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Ankara Yildirim Beyazıt University, class: OTHER, descriptionModule briefSummary: The aim of this study is to examine the effects of breathing exercises in women with primary dysmenorrhea., conditionsModule conditions: Dysmenorrhea, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 42, type: ESTIMATED, armsInterventionsModule interventions name: Breathing exercises, interventions name: Control, outcomesModule primaryOutcomes measure: Menstrual pain intensity, secondaryOutcomes measure: Menstrual symptoms, secondaryOutcomes measure: Life quality, secondaryOutcomes measure: Stress level, secondaryOutcomes measure: Sleep quality, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06321211, orgStudyIdInfo id: RECAS-0244, briefTitle: Development of a Novel Asian Mediterranean Diet and Its Acceptability in NAFLD, acronym: aMed, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-12-27, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Singapore Institute of Technology, class: OTHER, collaborators name: Singapore Health Services, descriptionModule briefSummary: The goal of this pre-intervention study is test the acceptability of Asian version of the Mediterranean diet to NAFLD patients.The main question\[s\] it aims to answer are:1. Whether Asian version of the Mediterranean diet that retains the nutritional composition and can be developed by mapping the components of the Mediterranean diet and finding substitute ingredients commonly eaten in Southeast Asia.2. Whether the 4-week menu cycle of newly developed novel Asian Mediterranean diet is acceptable among Singaporean local population.Participants will participate in taste test sessions to find out if the Asian Mediterranean diet meals are acceptable to people with NAFLD., conditionsModule conditions: Fatty Liver, Nonalcoholic, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 30, type: ESTIMATED, outcomesModule primaryOutcomes measure: Sensory Evaluation Test Score NAFLD, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2024-02-02, uploadDate: 2024-02-29T00:58, filename: Prot_SAP_000.pdf, size: 135277, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form: Consent Form Only, date: 2024-03-02, uploadDate: 2024-03-06T09:36, filename: ICF_001.pdf, size: 732118, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form: Participant Information Sheet, date: 2024-03-02, uploadDate: 2024-03-13T21:38, filename: ICF_002.pdf, size: 861264, hasResults: False
protocolSection identificationModule nctId: NCT06321198, orgStudyIdInfo id: iMSC-2001, briefTitle: A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-10, primaryCompletionDateStruct date: 2027-03-02, completionDateStruct date: 2027-03-02, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Anhui Provincial Hospital, class: OTHER_GOV, descriptionModule briefSummary: A study to evaluate the safety and preliminary efficacy of iMSC in subjects with SR-aGVHD, conditionsModule conditions: Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD), designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: iMSC, outcomesModule primaryOutcomes measure: Dose-Limiting Toxicity(DLT), primaryOutcomes measure: Adverse Event(AE),Serious Adverse Event(SAE),Treatment Emergent Adverse Event(TEAE)and Treatment Related Adverse Event(TRAE), secondaryOutcomes measure: Objective Response Rate(ORR), secondaryOutcomes measure: Overall Survival(OS), eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 70 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Anhui Provincial Hospital, status: RECRUITING, city: Hefei, state: Anhui, zip: 230036, country: China, contacts name: Zhu Xiaoyu, Ph.D, role: CONTACT, phone: +86 15255456091, email: xiaoyuz@ustc.edu.cn, contacts name: Sun Guangyu, role: CONTACT, phone: +86 13956970687, email: sunguangyu_vip@foxmail.com, geoPoint lat: 31.86389, lon: 117.28083, hasResults: False
protocolSection identificationModule nctId: NCT06321185, orgStudyIdInfo id: 2024/177, briefTitle: Laparoscopic Cholecystectomy and Quality of Recovery, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2024-08-25, completionDateStruct date: 2024-08-25, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Istanbul University, class: OTHER, descriptionModule briefSummary: This clinical trial aims to compare the Quality of Recovery-15 (QoR-15) scale scores in three groups of patients undergoing laparoscopic cholecystectomy. The first group will be applied subcostal transversus abdominis plane (subcostal TAP) block, the second group will receive local anesthetic infiltration into port sites, and the third group will receive only IV analgesics., conditionsModule conditions: Laparoscopic Cholecystectomy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The patients will be allocated randomly into three groups. Two groups will receive subcostal TAP block or port site local anesthetic infiltration, and the third group will not receive any intervention., primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: The subcostal TAP block and port-site infiltration will be applied after the patient has general anesthesia, so the patient will not know the allocated group. The healthcare providers who work in the ward and are responsible for the analgesic treatments will be blinded to the patient's group. The outcomes assessor who will question the QoR-15 scale at the 24th hour will also be blinded., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Subcostal TAP block, interventions name: Port site local anesthetic infiltration, interventions name: No intervention or local anesthetic administration, outcomesModule primaryOutcomes measure: Quality of Recovery-15 (QoR-15) scale, secondaryOutcomes measure: Postoperative rescue analgesic requirement, secondaryOutcomes measure: Consumption of postoperative opioid analgesics, secondaryOutcomes measure: Numerical Rating Scale (NRS) scores, secondaryOutcomes measure: Postoperative nausea and vomiting, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istanbul University Istanbul Medical Faculty, Department of Anesthesiology and Reanimation, status: RECRUITING, city: Istanbul, state: Fatih, zip: 34093, country: Turkey, contacts name: Muserref B Dincer, role: CONTACT, phone: +905321624712, email: mberildincer@gmail.com, contacts name: Ahmet K Koltka, role: CONTACT, email: koltkak@yahoo.com, contacts name: Muserref B Dincer, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06321146, orgStudyIdInfo id: LY2024-029-B, briefTitle: Evaluation of EEG Power Spectrum in Patients With Traumatic Coma, acronym: EPIC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2026-04-30, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: RenJi Hospital, class: OTHER, collaborators name: Beijing Tiantan Hospital, collaborators name: Xiangya Hospital of Central South University, collaborators name: The General Hospital of Eastern Theater Command, collaborators name: Anhui No.2 Provincial People's Hospital, descriptionModule briefSummary: Development of objective, reliable, and convenient assessment methods of disorders of consciousness is crucial. We aim to conduct multicenter prospective observational study and non-invasively collect EEG from patients with traumatic coma to analyze the sequential characteristics of EEG power spectrum, and explore their prognostic value for consciousness recovery., conditionsModule conditions: Coma, conditions: Brain Injuries, Traumatic, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 210, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: EEG power spectrum, secondaryOutcomes measure: Coma Recovery Scale-Revised (CRS-R), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Anhui No.2 Provincial People's Hospital, city: Hefei, state: Anhui, country: China, contacts name: Yongming Zhang, Dr., role: CONTACT, geoPoint lat: 31.86389, lon: 117.28083, locations facility: Beijing Tiantan Hospital, Capital Medical University, city: Beijing, state: Beijing, country: China, contacts name: Guoyi Gao, Dr., role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, locations facility: Xiangya Hospital, Central South University, city: Changsha, state: Hunan, country: China, contacts name: Jinfang Liu, Dr., role: CONTACT, geoPoint lat: 28.19874, lon: 112.97087, locations facility: The General Hospital of Eastern Theater Command, city: Nanjing, state: Jiangsu, country: China, contacts name: Chiyuan Ma, Dr., role: CONTACT, geoPoint lat: 32.06167, lon: 118.77778, locations facility: Brain Injury Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, city: Shanghai, state: Shanghai, zip: 201114, country: China, contacts name: Junfeng Feng, role: CONTACT, phone: +8613611860825, email: fengjfmail@163.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06321133, orgStudyIdInfo id: 5402589, briefTitle: High Flow Nasal Cannula Weaning in Acute Bronchiolitis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-13, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Kuopio University Hospital, class: OTHER, collaborators name: Central Finland Hospital District, collaborators name: Mikkeli Central Hospital, collaborators name: Siun sote, descriptionModule briefSummary: The goal of this clinical study is to compared two different strategies to end high flow nasal cannula treatment in acute bronchiolitis. This study compared the immediate ending of high flow treatment to weaning strategy, in which the flow rate is gradually decreased. The aim is to assess if the immediate ending shortens the hospitalization time and whether it is a safe strategy., conditionsModule conditions: Acute Bronchiolitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: High flow nasal cannula immediate ending, interventions name: High flow nasal cannula weaning, outcomesModule primaryOutcomes measure: Hospitalization time from randomization, secondaryOutcomes measure: Treatment failures, secondaryOutcomes measure: Readmission rate, secondaryOutcomes measure: Overall hospitalization time, eligibilityModule sex: ALL, minimumAge: 0 Months, maximumAge: 12 Months, stdAges: CHILD, contactsLocationsModule locations facility: Siun Sote, status: RECRUITING, city: Joensuu, country: Finland, contacts name: Paula Widgren, MD, PhD, role: CONTACT, phone: 0045813 330 8285, email: paula.widgren@siunsote.fi, geoPoint lat: 62.60118, lon: 29.76316, locations facility: Central Finland Hospital District, status: RECRUITING, city: Jyväskylä, country: Finland, contacts name: Milla Pitkänen, MD, role: CONTACT, phone: 0035814 2691811, email: milla.pitkanen@hyvaks.fi, geoPoint lat: 62.24147, lon: 25.72088, locations facility: Kuopio University Hospital, status: RECRUITING, city: Kuopio, country: Finland, contacts name: Ilari Kuitunen, MD, PhD, role: CONTACT, phone: +358447174910, email: ilari.kuitunen@uef.fi, contacts name: Marjo Renko, Professor, role: CONTACT, contacts name: Katri Backman, MD, PhD, role: SUB_INVESTIGATOR, contacts name: Miika Arvonen, MD, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 62.89238, lon: 27.67703, locations facility: Mikkeli Central Hospital, status: RECRUITING, city: Mikkeli, country: Finland, contacts name: Nicole Weisshoff, MD, role: CONTACT, phone: 0035815 3511, email: nicole.weisshoff@etelasavonha.fi, geoPoint lat: 61.68857, lon: 27.27227, hasResults: False
protocolSection identificationModule nctId: NCT06321120, orgStudyIdInfo id: 0749-21-HMO-CTIL, briefTitle: Using Chronobiology to Improve Lenvatinib Efficacy, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-01, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Hadassah Medical Organization, class: OTHER, descriptionModule briefSummary: The goal of this proof-of-concept clinical trial is to assess the efficacy and safety of chronobiology implementation into lenvatinib treatment regimens of thyroid cancer patients, via a mobile application.Participants will use a mobile application to follow variability-based physician approved drug administration schedules., conditionsModule conditions: Lenvatinib Treatment, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: An open-labeled, prospective, single-center proof-of-concept clinical trial lasting 14 weeks was conducted to investigate the impact of an algorithm-based regimen on enhancing lenvatinib effectiveness., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: variability-based lenvatinib regimen, outcomesModule primaryOutcomes measure: disease progression/ tumor response, secondaryOutcomes measure: Adverse effects occurrence, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hadassah Medical Organization, status: RECRUITING, city: Jerusalem, zip: 91120, country: Israel, contacts name: Hadas Lemberg, PhD, role: CONTACT, phone: +97226777572, email: lhadas@hadassah.org.il, geoPoint lat: 31.76904, lon: 35.21633, hasResults: False